Define Carcinoma of the Pancreas. Describe its clinical features, management and prognosis.

The Concept

Carcinoma of the pancreas is usually a ductal adenocarcinoma, and it is one of the most lethal of cancers because it presents late and behaves aggressively. About two-thirds arise in the head of the gland, where they tend to cause obstructive jaundice relatively early; tumours of the body and tail present later (with pain) and carry an even worse prognosis. Its location relative to the bile duct largely determines how it presents.

Risk Factors

The main risk factors are smoking (the strongest modifiable factor), chronic pancreatitis, diabetes mellitus, increasing age, obesity, and a family history.

Clinical Features

• Head of pancreas — painless, progressive obstructive jaundice (with pale stools, dark urine, pruritus), classically with a palpable gallbladder (Courvoisier's law), and weight loss.
• Body/tail — epigastric pain radiating to the back and weight loss, presenting late.
• General — anorexia and marked weight loss, new-onset diabetes, and migratory thrombophlebitis (Trousseau's sign).

Investigation & Staging

A pancreatic-protocol CT is central — it demonstrates the tumour and, critically, assesses resectability (involvement of the major vessels). CA 19-9 is a useful tumour marker for support and follow-up (not screening). MRCP/ERCP assesses the biliary obstruction (and allows stenting), endoscopic ultrasound with biopsy gives tissue, and staging laparoscopy detects peritoneal spread.

Management

Sadly, only a minority are resectable at diagnosis:

• Resectable disease (mostly head tumours) — a Whipple's procedure (pancreaticoduodenectomy), removing the head of pancreas, duodenum, distal bile duct and part of the stomach, followed by adjuvant chemotherapy.
• Unresectable or metastatic disease (the majority) — palliation: relieving jaundice with a biliary stent, controlling pain (including a coeliac plexus block), relieving duodenal obstruction (stent/bypass), and palliative chemotherapy.

WHY the Prognosis Is So Poor

The dismal outlook has clear reasons worth articulating. The pancreas has no capsule and a rich lymphatic and neural network, so tumours spread early — to lymph nodes, along nerves (causing the boring back pain), into the portal/mesenteric vessels, and to the liver and peritoneum. Symptoms are vague until the tumour obstructs the bile duct or invades locally, so most present with unresectable or metastatic disease. This biology, not a lack of treatment, is why five-year survival remains very low.

Assessing Resectability

The pivotal decision is whether the tumour is resectable, which turns on its relationship to the major vessels (the superior mesenteric artery and vein, portal vein and coeliac axis) on a dedicated pancreatic-protocol CT. Tumours are classified as resectable, 'borderline resectable', or locally advanced/metastatic. This assessment — together with staging laparoscopy to exclude peritoneal disease — determines whether a patient is offered a major curative operation or directed to palliation, sparing unfit or incurable patients futile surgery.

Palliation in Detail

Since most patients are palliative, relieving symptoms well is central. The three cardinal palliative problems are jaundice, duodenal obstruction and pain: jaundice is relieved by an endoscopic biliary stent (or a surgical bypass), gastric outlet/duodenal obstruction by a duodenal stent or gastrojejunostomy, and the characteristic back pain by strong analgesia and a coeliac plexus block/neurolysis. Palliative chemotherapy may prolong life, and early palliative-care involvement improves quality of life.

A Note on Periampullary Tumours

It is worth distinguishing pancreatic head cancer from the other 'periampullary' tumours — cancers of the ampulla of Vater, the distal bile duct, and the duodenum — which cluster around the same region and also present with obstructive jaundice. They are grouped because they are treated by the same operation (a Whipple's procedure), but ampullary and duodenal tumours generally have a better prognosis than pancreatic ductal adenocarcinoma, and may present earlier (with jaundice or bleeding). Recognising this group refines both the assessment and the prognostic discussion.

• Painless obstructive jaundice + palpable gallbladder (Courvoisier) + weight loss = carcinoma head of pancreas.
• CA 19-9 is the tumour marker (support/follow-up, not screening); pancreatic-protocol CT assesses resectability.
• Resectable head tumour → Whipple's (pancreaticoduodenectomy) + adjuvant chemo; most get palliation (biliary stent, chemo).

Whipple procedure is possible in only a minority at presentation.

• Usually ductal adenocarcinoma, most in the head; late, aggressive presentation and poor prognosis.
• Risk: smoking (strongest), chronic pancreatitis, diabetes, age, obesity, family history.
• Head → painless obstructive jaundice + palpable gallbladder (Courvoisier) + weight loss; body/tail → back pain, late; also new diabetes, Trousseau's sign.
• Pancreatic-protocol CT (diagnosis + resectability); CA 19-9 marker; MRCP/ERCP, EUS-biopsy, staging laparoscopy.
• Whipple's procedure for the few resectable tumours (+ adjuvant chemo); palliation (biliary stent, pain control, chemo) for the majority.